Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 8/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4987756 | 1.00 | CA2 (0.46) | CA2CA1CA7TDP1CYP2D6 | |
| SCHEMBL4464374 | 0.93 | CA1 (0.51) | CA2CA1CA7TDP1CYP2D6 | |
| SCHEMBL2389101 | 0.93 | CA1 (0.51) | CA2CA1CA7TDP1CYP2D6 | |
| SCHEMBL2388142 | 0.93 | CA1 (0.51) | CA2CA1CA7TDP1CYP2D6 | |
| SCHEMBL30434064 | 0.85 | CA2 (0.45) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL15872176 | 0.83 | CA2 (0.46) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL22584738 | 0.83 | CA2 (0.46) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL22584739 | 0.83 | CA2 (0.46) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL6841171 | 0.83 | CA2 (0.46) | CA2CA1CA7CYP2D6CTSK | |
| SCHEMBL24687980 | 0.83 | TDP1 (0.50) | CA2CA1CA7TDP1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080114010-A1 | Novel Substituted Imidazole Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-05-15 | — | — | US | disclosed |
| US-7301021-B2 | Substituted imidazole compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| CN-1134420-C | Novel substituted imidazole compounds | �������۸��¼��������������ι�˾ | 2004-01-14 | — | — | CN | disclosed |
| US-20030114452-A1 | Novel substituted imidazole compounds | SMITHKLINE BEECHAM CORPORATION | 2003-06-19 | — | — | US | disclosed |
| US-6489325-B1 | INHIBITORS OF CSBP/P38, ONE OF SEVERAL KINASES INVOLVED IN A STRESS-RESPONSE SIGNAL TRANSDUCTION, DECREASE THE SYNTHESIS OF A WIDE VARIETY OF PRO-INFLAMMATORY PROTEINS INCLUDING, IL-6, IL-8, GM-CSF, AND COX-2 | SMITHKLINE BEECHAM CORPORATION | 2002-12-03 | — | — | US | disclosed |
| CN-1261277-A | Novel substituted imidazole compounds | SMITHKLINE BEECHAM CORP (US) | 2000-07-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114452-A1 | Novel substituted imidazole compounds | CREBBP, MAPKAPK2, ATF1 | CA2 3710/4885CA1 4578/4885CA7 4331/4885 |
| US-20080114010-A1 | Novel Substituted Imidazole Compounds | CREBBP, MAPKAPK2, ATF1 | CA2 3710/4885CA1 4578/4885CA7 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.